ERBB2 and neoplasm: One of the key mechanisms of action (MOAs) of trastuzumab is ADCC (34), and as such, we compared the abilities of BsAb and trastuzumab in promoting ADCC using human PBMCs as effector cells and HER2+ NCI-N87 and HCC1954 tumor cells as target cells.